relatlimab (BMS-986016) - BMS
bemcentinib (BGB324) - Oncoinvent
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Tafinlar (dabrafenib) - Novartis
Cabometyx (cabozantinib tablet) - Exelixis
Predicting Targeted and Immunotherapeutic Response Outcomes in Melanoma With Single-Cell Raman Spectroscopy and Artificial Intelligence. (PubMed, JCO Precis Oncol) - Sep 10, 2026 - "Single-cell Raman spectroscopy combined with ML offers a scalable, prognostic platform to predict therapeutic resistance likelihood, with further potential to advance clinical, multiomic biomarker efforts for melanoma. Our approach may improve first- and second-line therapy selection assessments for precision medicine by providing rapid, nondestructive prediction of therapeutic response based on cellular spectral profiles." 
IO biomarker • Journal • Melanoma • Oncology • Solid Tumor
http://www.ncbi.nlm.nih.gov/pubmed/42715507
 
Amanda Gonçalves; Amanda Kirane; Ariel Stiber; Baba Ogunlade; Daniel Delitto; Fareeha Safir; Grayson E Rodriguez; Hsiu-Ju Hsu; James Agolia; Jay Chadokiya; Jeffrey Gu; Jennifer A Dionne; K Christopher Garcia; Kai Chang; Mamatha Serasanambati; Nhat Vu; Ojasvi Verma; Prabhjeet Singh; Saurabh Sharma
 
Sep 10, 2026
 
Prev Next